Apotex announces leadership changes
Mar 30, 2026Toronto, ON – March 30, 2026 – . Apotex, the Canadian-based global health company, today announced key changes to its executive leadership structure designed to strengthen its long-term strategic direction and accelerate the company’s next phase of growth.
Allan Oberman has decided to step down as CEO of Apotex. As part of this transition, Allan will resume his role as a member of the Board of Apotex, where he will continue to oversee the company’s strategic priorities and long-range planning. Since 2023, Mr. Oberman has been President and CEO of Apotex.
At the same time, Jeff Watson has been appointed President and Chief Executive Officer. Mr. Watson returns to the business and will assume full responsibility for leading Apotex’s global operations, driving the company’s business strategy, operational performance, and growth agenda. He has been a leader at Apotex for more than 20 years, including as President and CEO from 2018 to 2023. In June 2023, he became a member of Apotex’s Board of Directors and continued to oversee the business strategy in that role.
"Allan’s deep industry expertise and strong leadership have been instrumental in shaping Apotex’s strategic direction," said Aaron Davenport, Chairman of the Board and Managing Director at SK Capital Partners, LP. "As a member of the Board of Directors, he will continue to be engaged in the company’s Journey of Health strategy. We are also thrilled to welcome Jeff back to Apotex as our CEO. His track record of delivering results, combined with his commitment to patient access and industry innovation, makes him the ideal leader to lead the future operations and growth of the company."
These leadership changes are effective immediately.
For more information:
Catherine Thomas
Vice President, Global Communication
[email protected]
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Learn more about us at www.apotex.com.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Nov 17, 2026
Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes
TORONTO, ON, November 16, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced the launch of APO-LINAGLIPTIN™ (linagliptin tablets), the latest addition to its portfolio of medicines.
-
Nov 12, 2026
Apotex Announces Second Quarter 2027 Results
TORONTO, ON, November 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada’s largest pharmaceutical company, today announced its financial and operating results for the three and six months ended September 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.